Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Page 1
Neurogenic Lower Urinary Tract Dysfunction in the First Year After Spinal Cord Injury: A Descriptive Study of Urodynamic Findings.
Kozomara M, Birkhäuser V, Anderson CE, Bywater M, Gross O, Kiss S, Knüpfer SC, Koschorke M, Leitner L, Mehnert U, Sadri H, Sammer U, Stächele L, Tornic J, Brinkhof MWG, Liechti MD, Kessler TM. Kozomara M, et al. Among authors: kiss s. J Urol. 2023 Jan;209(1):225-232. doi: 10.1097/JU.0000000000003021. Epub 2022 Oct 20. J Urol. 2023. PMID: 36263681
As early treatment based on urodynamic findings might reduce the risk of deterioration of upper and lower urinary tract function, thereby improving long-term outcomes, there is need for further research regarding recommendations for a urodynamic follow-up schedule during t …
As early treatment based on urodynamic findings might reduce the risk of deterioration of upper and lower urinary tract function, thereby im …
90Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates.
Szakács Z, Lal A, Kristensen J, Farkas N, Ritter Z, Kiss S, Alizadeh H, Balikó A. Szakács Z, et al. Among authors: kiss s. Adv Radiat Oncol. 2021 Dec 26;7(5):100882. doi: 10.1016/j.adro.2021.100882. eCollection 2022 Sep-Oct. Adv Radiat Oncol. 2021. PMID: 36148378 Free PMC article.
One case of progression was registered (median EFS: 33 months [Q(1)-Q(3) range, 30.5-44 months]). (90)YIT had acceptable short- and long-term safety profiles. CONCLUSIONS: The findings suggest that patients with NHL may benefit from (90)YIT as salvage treatment if ASCT is …
One case of progression was registered (median EFS: 33 months [Q(1)-Q(3) range, 30.5-44 months]). (90)YIT had acceptable short- and long- …
Primary pelvic exenteration: Our experience with 23 patients from a single institution.
Gheorghe M, Cozlea AL, Kiss SL, Stanca M, Căpîlna ME, Bacalbașa N, Moldovan AA. Gheorghe M, et al. Among authors: kiss sl. Exp Ther Med. 2021 Oct;22(4):1060. doi: 10.3892/etm.2021.10494. Epub 2021 Jul 26. Exp Ther Med. 2021. PMID: 34434274 Free PMC article.
Primary pelvic exenteration may be related with various postoperative complications, without high perioperative morality and with long-term survival....
Primary pelvic exenteration may be related with various postoperative complications, without high perioperative morality and with long-te …
Abdominal radical trachelectomy as fertility-sparing management for early stages of cervical cancer: Our experience in 18 cases.
Kiss SL, Fandi A, Cozlea AL, Gheorghe M, Stanca M, Bacalbașa N, Moldovan AA, Căpîlna ME. Kiss SL, et al. Exp Ther Med. 2021 Jul;22(1):674. doi: 10.3892/etm.2021.10106. Epub 2021 Apr 23. Exp Ther Med. 2021. PMID: 33986839 Free PMC article.
Four out of the 18 patients were operated on during pregnancy between 14 and 20 weeks; 2 of them gave birth at term, 2 of them aborted shortly after the surgery. Two vaginal recurrences were recorded; both were managed by hysterectomy, partial colpectomy and adjuvan …
Four out of the 18 patients were operated on during pregnancy between 14 and 20 weeks; 2 of them gave birth at term, 2 of them …
Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema.
Gelfman CM, Grishanin R, Bender KO, Nguyen A, Greengard J, Sharma P, Nieves J, Kiss S, Gasmi M. Gelfman CM, et al. Among authors: kiss s. J Ocul Pharmacol Ther. 2021 Apr;37(3):181-190. doi: 10.1089/jop.2021.0001. J Ocul Pharmacol Ther. 2021. PMID: 33835848 Free PMC article.
Ocular safety was evaluated following long-term suppression of VEGF by clinical scoring (inflammatory parameters) as well as optical coherence tomography (OCT) and electroretinography (ERG). ...These results demonstrate that a single intravitreal administration of ADVM-022 …
Ocular safety was evaluated following long-term suppression of VEGF by clinical scoring (inflammatory parameters) as well as optical …
Effect of Growth Hormone on Neuropsychological Outcomes and Quality of Life of Patients with Traumatic Brain Injury: A Systematic Review.
Szarka N, Szellar D, Kiss S, Farkas N, Szakacs Z, Czigler A, Ungvari Z, Hegyi P, Buki A, Toth P. Szarka N, et al. Among authors: kiss s. J Neurotrauma. 2021 Jun 1;38(11):1467-1483. doi: 10.1089/neu.2020.7265. Epub 2021 Apr 23. J Neurotrauma. 2021. PMID: 33677992 Free PMC article.
We performed a literature search in PubMed, Embase, and Central() databases from inception to October 2019. We extracted data on each term of severity (mild-moderate-severe) of TBI with and without GHD, time since injury, parameters of growth hormone treatment (dosing, len …
We performed a literature search in PubMed, Embase, and Central() databases from inception to October 2019. We extracted data on each ter …
Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates.
Kiss S, Oresic Bender K, Grishanin RN, Hanna KM, Nieves JD, Sharma P, Nguyen AT, Rosario RJ, Greengard JS, Gelfman CM, Gasmi M. Kiss S, et al. Transl Vis Sci Technol. 2021 Jan 29;10(1):34. doi: 10.1167/tvst.10.1.34. eCollection 2021 Jan. Transl Vis Sci Technol. 2021. PMID: 33532145 Free PMC article.
PURPOSE: To evaluate the long-term safety of vascular endothelial growth factor (VEGF) suppression with sustained aflibercept expression after a single intravitreal injection (IVI) of ADVM-022, an anti-VEGF gene therapy, in non-human primates (NHPs). ...RPE integrity was m …
PURPOSE: To evaluate the long-term safety of vascular endothelial growth factor (VEGF) suppression with sustained aflibercept express …
Vitamin D supplementation in patients with cystic fibrosis: A systematic review and meta-analysis.
Juhász MF, Varannai O, Németh D, Szakács Z, Kiss S, Izsák VD, Martonosi ÁR, Hegyi P, Párniczky A. Juhász MF, et al. Among authors: kiss s. J Cyst Fibros. 2021 Sep;20(5):729-736. doi: 10.1016/j.jcf.2020.12.008. Epub 2020 Dec 19. J Cyst Fibros. 2021. PMID: 33349585 Free article.
Future RCTs should include outcomes of past studies and apply longer follow-up periods to document long-term patient-important outcomes....
Future RCTs should include outcomes of past studies and apply longer follow-up periods to document long-term patient-important outcom …
Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2.
Sondhi D, Kaminsky SM, Hackett NR, Pagovich OE, Rosenberg JB, De BP, Chen A, Van de Graaf B, Mezey JG, Mammen GW, Mancenido D, Xu F, Kosofsky B, Yohay K, Worgall S, Kaner RJ, Souwedaine M, Greenwald BM, Kaplitt M, Dyke JP, Ballon DJ, Heier LA, Kiss S, Crystal RG. Sondhi D, et al. Among authors: kiss s. Sci Transl Med. 2020 Dec 2;12(572):eabb5413. doi: 10.1126/scitranslmed.abb5413. Sci Transl Med. 2020. PMID: 33268510 Free PMC article. Clinical Trial.
The therapy was associated with a variety of expected adverse events, none causing long-term disability. Induction of systemic anti-AAVrh.10 immunity was mild. ...
The therapy was associated with a variety of expected adverse events, none causing long-term disability. Induction of systemic anti-A …
Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease.
Dohos D, Hanák L, Szakács Z, Kiss S, Párniczky A, Erőss B, Pázmány P, Hegyi P, Sarlós P. Dohos D, et al. Among authors: kiss s. Aliment Pharmacol Ther. 2021 Jan;53(2):220-233. doi: 10.1111/apt.16182. Epub 2020 Nov 28. Aliment Pharmacol Ther. 2021. PMID: 33249621 Free PMC article. Review.
CONCLUSION: Continuing immunomodulator monotherapy should remain the preferred approach among patients with Crohn's disease, although long-term toxicity is a concern. Further randomised controlled trials are warranted in ulcerative colitis and on combination regimens inclu …
CONCLUSION: Continuing immunomodulator monotherapy should remain the preferred approach among patients with Crohn's disease, although long- …
35 results